FinanzNachrichten.de: Nachrichten zu TAKEDA PHARMACEUTICAL CO LTD

Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology Lexington, Mass. - November 10, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the...

CHMP recommends EU marketing authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A If approved, ADYNOVI, built on ADVATE [Antihemo...

SAINT HELIER (dpa-AFX) - Shire plc (SHPG, SHP.L), a biotechnology company focused on rare diseases, announced Monday that the Committee for Medicinal Products for Human Use or CHMP of the European...

Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of Directors November 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases,...

Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of DirectorsNovember 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, ...

(Ergänzt mit der Ernennung Dittrichs zum CFO von Shire, Kursentwicklung aktualisiert) Zürich (awp) - Im Management des Technologiekonzerns Sulzer kommt es zu einer Änderung. Der bisherige Finanzche...

SAINT HELIER (dpa-AFX) - After showing an early move to the downside, shares of Shire (SHPG) continue to see considerable weakness in late-day trading on Monday. Shire is currently down by 3.6 per...

BLOCK LISTING SIX MONTHLY RETURNNovember 24, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)+------------------------------------------+-----------------------------------+ |Name of applicant: |Shire pl...

U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients Cambridge,...

Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer Howard Mayer, MD to become Chief Medical Officer Cambridge, MA - December 1, 2017 - Shire plc (L...

Total Voting RightsDecember 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the 'Company'), in accordance with 5.6.1R of the Financial Conduct Authority's (the 'FCA') Disclosure Guidance and Transpa...

Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill Technology for the Oral Delivery of Factor TherapyShire obtains exclusive rights to conduct research on, evalu...

SAINT HELIER (dpa-AFX) - Shire plc (SHP.L, SHPG) and Rani Therapeutics, an InCube Labs company, announced a collaboration to exclusively conduct research on the use of the Rani Pill technology for...

Chief Financial Officer updateDecember 8, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, announced on August 21, 2017, that Jeff Poulton, Chief Financial Of...

New Formulation of ONCASPAR (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) Freeze-dried, or lyophilized, formulation aims to improve...

SAINT HELIER (dpa-AFX) - Shire plc (SHP.L, SHPG) announced that the European Commission has granted Marketing Authorization for lyophilized ONCASPAR (pegaspargase), as a component of antineoplasti...

Director DeclarationDecember 19, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the 'Company') announces that Bill Burns, Senior Independent Director of the Company, was appointed Vice- Chairman and D...

Shire said on Tuesday that clinical trials for a drug to treat Hunter syndrome in children, SHP609, failed to meet their primary and secondary endpoints. SHP609 is an investigational formulation of...

Director/PDMR ShareholdingDecember 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)Notification of transactions by persons discharging managerial responsibilities+--+---------------------------------...

Latest Images